Mechanism of resistance to cetuximab therapy in colorectal cancer: Possible role of antibodies to immunoglobulin allotypes.
作者信息
Pandey Janardan P
出版信息
MAbs. 2012 Sep-Oct;4(5):553-4. doi: 10.4161/mabs.21311. Epub 2012 Jul 23.
Abstract
摘要
相似文献
1
Mechanism of resistance to cetuximab therapy in colorectal cancer: Possible role of antibodies to immunoglobulin allotypes.结直肠癌中对西妥昔单抗治疗耐药的机制：针对免疫球蛋白同种异型抗体的可能作用。
MAbs. 2012 Sep-Oct;4(5):553-4. doi: 10.4161/mabs.21311. Epub 2012 Jul 23.
2
Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes.不同 GM 同种型表达的免疫球蛋白 G1 对曲妥珠单抗和西妥昔单抗诱导的癌细胞细胞毒性的差异抑制。
Clin Exp Immunol. 2011 Dec;166(3):361-5. doi: 10.1111/j.1365-2249.2011.04477.x.
3
Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study.IgG1 同种异型差异与抗阿达木单抗形成之间令人惊讶的负相关：一项队列研究。
Arthritis Res Ther. 2010;12(6):R221. doi: 10.1186/ar3208. Epub 2010 Dec 27.
4
Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy.患有结直肠癌且KRAS分子状态异质性的患者对基于西妥昔单抗的化疗有反应。
J Clin Oncol. 2010 Dec 20;28(36):e756-8. doi: 10.1200/JCO.2010.30.5011. Epub 2010 Sep 20.
5
Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.广谱 RTK 靶向治疗通过载体免疫预防克服结直肠癌中分子异质性驱动的西妥昔单抗耐药性。
Cancer Lett. 2016 Nov 1;382(1):32-43. doi: 10.1016/j.canlet.2016.08.022. Epub 2016 Aug 26.
6
Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.单克隆抗体在结直肠癌中对表皮生长因子受体的临床应用。
Oncology (Williston Park). 2007 Jul;21(8):964-70; discussion 970, 974, 976-7.
7
Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.用于治疗转移性结直肠癌的表皮生长因子受体单克隆抗体
Pharmacotherapy. 2008 Jun;28(6):742-54. doi: 10.1592/phco.28.6.742.
8
Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.用于治疗结直肠癌的抗表皮生长因子受体单克隆抗体：西妥昔单抗和帕尼单抗的研发
J Clin Pharmacol. 2012 Feb;52(2):128-55. doi: 10.1177/0091270010395940.
9
The road to resistance: EGFR mutation and cetuximab.抗药之路：EGFR突变与西妥昔单抗
Nat Med. 2012 Feb 6;18(2):199-200. doi: 10.1038/nm.2646.
10
Vaccination against tumour blood vessels in colorectal cancer.结直肠癌中针对肿瘤血管的疫苗接种。
Eur J Surg Oncol. 2014 Feb;40(2):133-6. doi: 10.1016/j.ejso.2013.11.025. Epub 2013 Dec 13.
引用本文的文献
1
Innate and Acquired Resistance to Anti-EGFR Therapy-Letter.对表皮生长因子受体（EGFR）靶向治疗的固有和获得性耐药——信函
Clin Cancer Res. 2020 Apr 1;26(7):1773. doi: 10.1158/1078-0432.CCR-19-3935.
2
Opportunities to exploit non-neutralizing HIV-specific antibody activity.利用非中和性HIV特异性抗体活性的机会。
Curr HIV Res. 2013 Jul;11(5):365-77. doi: 10.2174/1570162x113116660058.
3
Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology.基于 WAVE 技术的 KRAS 原癌基因在结直肠癌（CRC）中的异质性。
Exp Mol Pathol. 2013 Aug;95(1):74-82. doi: 10.1016/j.yexmp.2013.01.004. Epub 2013 Mar 22.
本文引用的文献
1
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.结直肠癌中 KRAS 突变的出现和抗 EGFR 治疗的获得性耐药。
Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156.
2
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.鉴定出表皮生长因子受体胞外结构域的一个突变，导致结直肠癌对西妥昔单抗产生耐药性。
Nat Med. 2012 Jan 22;18(2):221-3. doi: 10.1038/nm.2609.
3
A new synthesis for antibody-mediated immunity.一种新的抗体介导免疫的综合方法。
Nat Immunol. 2011 Dec 16;13(1):21-8. doi: 10.1038/ni.2184.
4
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.ERBB2 信号的激活导致对 EGFR 导向的治疗性抗体西妥昔单抗的耐药性。
Sci Transl Med. 2011 Sep 7;3(99):99ra86. doi: 10.1126/scitranslmed.3002442.
5
2nd Charles Richet et Jules Héricourt workshop: therapeutic antibodies and anaphylaxis; May 31-June 1, 2011, Tours, France.第二届查尔斯·里歇与朱尔斯·赫里厄特研讨会：治疗性抗体与过敏反应；2011 年 5 月 31 日-6 月 1 日，法国图尔。
MAbs. 2011 Sep-Oct;3(5):417-21. doi: 10.4161/mabs.3.5.17485. Epub 2011 Sep 1.
6
Human immunoglobulin allotypes: possible implications for immunogenicity.人类免疫球蛋白同种型：对免疫原性的可能影响。
MAbs. 2009 Jul-Aug;1(4):332-8. doi: 10.4161/mabs.1.4.9122.
7
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.西妥昔单抗诱导的过敏反应及针对α-1,3-半乳糖的特异性IgE
N Engl J Med. 2008 Mar 13;358(11):1109-17. doi: 10.1056/NEJMoa074943.
8
The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen.免疫球蛋白重链恒定区影响抗体可变区与抗原相互作用的动力学和热力学参数。
J Biol Chem. 2007 May 4;282(18):13917-27. doi: 10.1074/jbc.M700661200. Epub 2007 Mar 12.
9
ANTIBODY TO HEREDITARY HUMAN GAMMA-GLOBULIN (GM) FACTOR RESULTING FROM MATERNAL-FETAL INCOMPATIBILITY.母婴血型不合导致的针对遗传性人类γ球蛋白（GM）因子的抗体。
Science. 1964 Jul 10;145(3628):170-1. doi: 10.1126/science.145.3628.170.
10
Advances in human immunoglobulin allotypes.人类免疫球蛋白同种异型的研究进展。
Exp Clin Immunogenet. 1995;12(3):191-7. doi: 10.1159/000424871.
Zotero 插件